Research and Markets has announced the addition of the "Hidradenitis Suppurativa - Pipeline Review, H2 2016" report to their offering.
Hidradenitis Suppurativa pipeline therapeutics constitutes close to 10 molecules. which approximately 10 molecules are developed by Companies. Our latest report Hidradenitis Suppurativa - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Hidradenitis Suppurativa Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 5 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/drs2xn/hidradenitis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010005708/en/Business Wire
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.